Immunovaccine Inc. today announced that it has entered into an agreement with Incyte Corporation (NASDAQ: INCY) to expand their ongoing ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian CancerApril 24, 2018 7:05 AM Incyte (INCY) PT Raised to $77 at RBC Capital; 'Base Case'April 24, 2018 6:29 AM Eli Lilly & Co. (LLY) & Incyte Corporation (INCY) Confirms FDA Advisory Committee Recommends Approval of Baricitinib 2mg and Against 4mgApril 24, 2018 6:01 AM Incyte (INCY) PT Lowered to $75 at SunTrust Robinson HumphreyApril 24, 2018 1:06 AM FDA Votes 10-5 to Back Incyte (INCY) and Lilly's (LLY) Baricitinib 2 mg, Votes 5-10 Against 4 mgApril 23, 2018 4:54 PM Incyte (INCY), Lilly (LLY) Low Dose Baricitinib Wins FDA Panel Vote on Safety; High Does Fails to Win Panel Vote on Safety - BloombergApril 23, 2018 4:41 PM Incyte (INCY), Eli Lilly (LLY) Panel Going More Favorably Than Previously Suggested - RBCApril 23, 2018 12:43 PM